Totient operates an AI-driven platform that leverages tertiary lymphoid structures (TLSs) to identify tissue-specific antigens and reconstruct high-affinity human antibodies from affected tissues. The company mines samples from patients with exceptional immune responses, beginning with a population of over 50,000 samples, and has reconstructed antibodies against known and novel extracellular oncology targets such as GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, and GPR83. Its human-derived antibodies are highly specific to tissue-specific antigens and are positioned for development as cell therapies, antibody-drug conjugates (ADCs), and bispecifics. Totient emerged from stealth concurrent with a $10M seed financing, which provides initial capital to advance its discovery pipeline. The company has adapted its platform to discover COVID-19 antibodies and announced a collaboration with Ginkgo Bioworks to reconstruct anti‑SARS‑CoV‑2 antibodies from bronchoalveolar lavage fluid (BALF) samples. Focusing on BALF samples aims to access a previously unexplored source of therapeutic candidates beyond typical blood-derived efforts.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2020